Reprogramming the tumor microenvironment via TFF3 targeting: a potential novel avenue to boost CAR-T cell therapy in...

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• CAR-T cell therapy is successful in blood cancers but faces challenges in solid tumors due to the tumor microenvironment (TME).
• The TME in solid tumors is dense, immunosuppressive, and has aberrant vasculature, hindering CAR-T cell infiltration and function.
• Trefoil Factor Family 3 (TFF3) is upregulated in solid tumors, promoting cancer progression, immune evasion, and therapy resistance.

Purpose of the Study:

• To explore how TFF3 signaling contributes to tumor progression and immune escape in solid tumors.
• To investigate the potential of TFF3 inhibition in reshaping the TME to improve CAR-T cell therapy efficacy.
• To discuss strategies for selective TFF3 blockade and potential combination therapies.

Main Methods:

• Review of existing literature on TFF3, tumor microenvironment, and CAR-T cell therapy.
• Analysis of TFF3's role in cancer cell proliferation, immune suppression, angiogenesis, and fibrosis.
• Exploration of potential therapeutic strategies targeting TFF3.

Main Results:

• TFF3 promotes tumor progression, immune suppression, angiogenesis, and fibrosis within the TME.
• Inhibiting TFF3 may reduce immunosuppression, normalize vasculature, and disrupt pro-tumorigenic interactions.
• TFF3 also plays a protective role in healthy tissues, necessitating careful inhibition strategies.

Conclusions:

• TFF3 is a significant contributor to the challenges faced by CAR-T cell therapy in solid tumors.
• Targeting TFF3 offers a promising strategy to enhance CAR-T cell efficacy by modulating the TME.
• Further research is needed to develop safe and effective TFF3-targeted therapies for solid tumors, potentially as combination treatments or preconditioning steps.